Abstract: This invention provides methods for producing furfural-urea resins and adhesives. The includes dissolving urea in hot water to produce a hot aqueous solution, mixing furfural with the aqueous solution, adding an acid catalyst such as maleic anhydride to the furfural containing aqueous solution upon which a resinification reaction begins immediately. The resinification reaction is quenched by cooling to a pre-selected temperature to produce a resin or adhesive.

Abstract: This invention is a method preparing solutions or mixtures of oligimer or polymer in a solution of polymerizable monomer, applying that solution to the surface of a solid porous substance like wood, heating to drive the mixture into the surface zone of the substance and causing the polymerizable monomer to cure. This produces a reinforced, hardened, protective shell around the porous substance.

Abstract: This invention provides methods for producing furfural-urea resins and adhesives. The includes dissolving urea in hot water to produce a hot aqueous solution, mixing furfural with the aqueous solution, adding an acid catalyst such as maleic anhydride to the furfural containing aqueous solution upon which a resinification reaction begins immediately. The resinification reaction is quenched by cooling to a pre-selected temperature to produce a resin or adhesive.

Abstract: This invention provides water-based furfural-urea resins for impregnation of same into wood in order to impart decay, mold, marine borer and termite resistance and improve moisture resistance and mechanical properties. The waterborne wood modification composition for impregnation into wood, includes water, furfural, urea, an acidic catalyst, and a buffer present in an amount to give a pH in a range from about 2.96 to about 5.13.

Abstract: This invention provides methods of furfural-urea modification of wood, and more particularly the present invention relates to the impregnation, and polymerization of, furfural-urea formulations under conditions of high weight percent gain (WPG) into wood. Wood is modified by impregnating wood first with furfural, thereafter impregnating the wood with a solution of urea, water and an acidic catalyst for polymerizing the mixture of furfural and urea in the wood. The wood is then dried and cured at the same time.

Abstract: X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed.

Abstract: Method and apparatus for mounting a sample comprising a crystal for X-ray crystallographic analysis, a method for aligning a sample comprising a crystal for X-ray crystallographic analysis, which sample is mounted on a positioning device, and a method for determining the structure of a sample containing a crystal by means of X-ray crystallography.

Abstract: Method for mounting a sample comprising a crystal for X-ray crystallographic analysis, a method for aligning a sample comprising a crystal for X-ray crystallographic analysis, which sample is mounted on a positioning device, and a method for determining the structure of a sample containing a crystal by means of X-ray crystallography. The method includes activating a robot so that the tool retrieves the crystal holder, receives a sufficient amount of a fluid to maintain the crystal in the crystal holder at a temperature not in excess of about 160 degrees K, transfers the retrieved crystal holder to a positioning device, and mounts the transferred crystal holder on the positioning device, whereby the crystal in the retrieved crystal holder is maintained at a temperature not in excess of about 160 degrees K.

Abstract: X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed.

Abstract: Method and apparatus for mounting a sample comprising a crystal for X-ray crystallographic analysis, a method for aligning a sample comprising a crystal for X-ray crystallographic analysis, which sample is mounted on a positioning device, and a method for determining the structure of a sample containing a crystal by means of X-ray crystallography.

Abstract: Method and apparatus for mounting a sample comprising a crystal for X-ray crystallographic analysis, a method for aligning a sample comprising a crystal for X-ray crystallographic analysis, which sample is mounted on a positioning device, and a method for determining the structure of a sample containing a crystal by means of X-ray crystallography.

Abstract: Method and apparatus for mounting a sample comprising a crystal for X-ray crystallographic analysis, a method for aligning a sample comprising a crystal for X-ray crystallographic analysis, which sample is mounted on a positioning device, and a method for determining the structure of a sample containing a crystal by means of X-ray crystallography.

Abstract: X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed. The target is exposed to the test samples by either co-crystallizing a biomolecule in the presence of one or more test samples or soaking the biomolecule crystal in a solution of one or more test samples. In another embodiment, structural information from ligand/receptor complexes are used to design ligands that bind tighter, that bind more specifically, that have better biological activity or that have better safety profile. A further embodiment of the invention comprises identifying or designing biologically-active moieties by the instant process.

Abstract: The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

Abstract: The present invention relates to a class of heptapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

Abstract: Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.

Abstract: Disclosed are 3',3'-N-bisdesmethyl-3',3'-N-bis-substituted-6-O-methyl-11-deoxy-11,12-cyc lic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: Disclosed are 3'-N-desmethyl-3'-N-substituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: The present invention provides a class of decapeptide compounds which are potent antagonists of LHRH activity and which have the structure A.sup.1 -D.sup.2 -E.sup.3 -G.sup.4 -J.sup.5 -L.sup.6 -M.sup.7 -Q.sup.8 -R.sup.9 -T.sup.10. The compounds of the percent invention are characterized by having an .OMEGA.-amino-functionalized side chain on the D-aminoacyl residue at position 6. The .OMEGA.-amino group of this side chain is further derivatized by the attachment of an extending group which likewise has a terminal amino group which is capped by an acyl group.